Cefepime versus ticarcillin and clavulanate potassium and aztreonam for febrile neutropenia therapy in high-dose chemotherapy patients

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 3, 2003, Pages 285-288

  Fleming, Donald R ^a   Ziegler, Craig ^b   Baize, Timothy ^b   Mudd, Leslie ^b   Goldsmith, George H ^b   Herzig, Roger H ^b  

^a Bierhaus Center   (United States)

^b NONE

Author keywords

Aztreonam; Cefepime; HDC; Hematopoetic stem cell transplantation; Neutropenia; Ticarcillin and clavulanate potassium

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; AZTREONAM; CEFEPIME; CLAVULANIC ACID; TICARCILLIN; TIMENTIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BLOOD CULTURE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; THROAT CULTURE; TREATMENT OUTCOME; URINE CULTURE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; AZTREONAM; CEPHALOSPORINS; CLAVULANIC ACID; COSTS AND COST ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; FEVER; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TICARCILLIN;

EID: 0038517759     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200306000-00016     Document Type: Article

References (22)

1. Body GP. Antibiotics in patients with neutropenia. Arch Intern Med 1984;144:1845-51.
2. Pizzo PA. Fever in immunocompromised patients. N Engl J Med 1999;34:893-900.
3. Quadri TL, Brown AE. Infectious complications in the critically ill patient with cancer. Semin Oncol 2000;27:335-46.
4. Sonis ST, Sonis AL, Leiberman A. Oral complications in patients receiving treatment for malignancies other than that of the head and neck. J Am Dental Assoc 1978;97:468-72.
5. Rapoport AP, Miller Watelet LF, Linder T, et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem cell transplants. J Clin Oncol 1999;17:2446-53.
6. Wardley AM, Jayson GC, Swindell R, et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haematopoietic progenitor rescue. Br J Haematol 2000;110:242-99.
7. Carmeli Y, Jamore MH, Huskins C. The association between antecedent vancomycin treatment and hospital acquired vancomycin resistant enterococcal: a net analysis. Arch Intern Med 1999; 159:2461-8.
8. Kuehnelt MJ, Jerrigan JA, Pullen AL, et al. Association between mucositis severity and vancomycin resistant enterococcal infection in hospitalized cancer patients. Infect Control Hosp Epidemiol 1999;20:660-31.
9. Bharnani SM, Drake JA, Forrest A, et al. A nationwide multicenter, case controlled study comparing risk factors, treatment and outcome for vancomycin resistant and susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000;36:145-58.
10. Kapur D, Dorsky D, Feingold JM, et al. Incidence and outcome of vancomycin resistant enterococcal bacteremia following autologous peripheral blood stem cell transplant. Bone Marrow Transplant 2000;25:147-52.
11. Klastersky J. Empiric treatment of infection during granulocytopenia. Ann Oncol 1991;1:255-61.
12. Hughes W, Armstrong D, Bodey GP, et al. 1997 guidelines of the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997;25:551-73.
13. Yamamura D, Guculp R, Carlisle P, et al. Open randomized study of cefapime versus piperacillin-gentamycin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother 1997; 41:1704-8.
14. Behre G, Link H, Maschmeyer G, et al. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. Ann Hematol 1998;76:73-80.
15. Fraser IS, Denning DW. Empiric amphotericin therapy: the need for reappraisal. Blood Rev 1993;7:208-14.
16. StatXact 3.0.2 for Windows. Cambridge, MA: CYTEL Software Corp., 1996.
17. SPSS for Windows, Rel. 10.0.0. Chicago: SPSS Inc. 1999.
18. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998;17:873-90.
19. Lowry R. (1998-2001). VassarStats. Web Site for Statistical Computation. Available at: http://faculty.vassar.edu/~lowry/VassarStats.html. Accessed May 7, 2001.
20. nQuery Advisor, Rel. 4.0. Cork, Ireland: Statistical Solutions Ltd., 2000.
21. NCCN practice guidelines for fever and neutropenia. Oncology 1999;13:197-259.
22. Sugar AM. Empiric treatment of fungal infections in the neutropenic host, Review of the literature and guidelines for use. Arch Intern Med 1990;150:2258-64.